Details
| Stereochemistry | MIXED |
| Molecular Formula | 2C20H37O7S.Ca |
| Molecular Weight | 883.215 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O.CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O
InChI
InChIKey=DWKPZOZZBLWFJX-UHFFFAOYSA-L
InChI=1S/2C20H38O7S.Ca/c2*1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h2*16-18H,5-15H2,1-4H3,(H,23,24,25);/q;;+2/p-2
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Monolayer of aerosol-OT surfactants adsorbed at the air/water interface: an atomistic computer simulation study. | 2005 Jan 13 |
|
| Investigation of micelle formation by fluorescence correlation spectroscopy. | 2005 Jul 14 |
|
| Vibrational relaxation of azide in formamide reverse micelles. | 2005 Jul 7 |
|
| On the temperature percolation in a w/o microemulsion in the presence of organic derivatives of chalcogens. | 2005 May 19 |
|
| Real structure of formamide entrapped by AOT nonaqueous reverse micelles: FT-IR and 1H NMR studies. | 2005 Nov 10 |
|
| Efficient gene transfection using chitosan-alginate core-shell nanoparticles. | 2006 |
|
| Nucleation and growth characteristics of a binary low-mass organogel. | 2006 Aug 15 |
|
| Aggregation behavior in mixed system of double-chained anionic surfactant with single-chained nonionic surfactant in aqueous solution. | 2006 Jul 15 |
|
| Sensing behaviors of polypyrrole nanotubes prepared in reverse microemulsions: effects of transducer size and transduction mechanism. | 2006 Jul 27 |
|
| Electrochemical extraction of proteins by reverse micelle formation. | 2006 Jun 20 |
|
| Tuning the cooperativity of the helix-coil transition by aqueous reverse micelles. | 2006 Jun 22 |
|
| Photodetachment of ferrocyanide in reverse micelles. | 2006 May 18 |
|
| Simultaneous determination of natural and synthetic estrogens by EKC using a novel microemulsion. | 2006 Nov |
|
| Hydrogen bond lifetime dynamics at the interface of a surfactant monolayer. | 2006 Nov 23 |
|
| An insight into the mechanism of protein separation by colloidal gas aphrons (CGA) generated from ionic surfactants. | 2006 Nov 7 |
|
| Spectrofluorimetric determination of tin in canned foods. | 2006 Oct 11 |
|
| [Chemotaxis as a method for testing of the biological effects of silver nanoparticles]. | 2006 Sep-Oct |
|
| Study of confined 5-aza[5]helicene in ytterbium(III) bis(2-ethylhexyl) sulfosuccinate reversed micelles. | 2007 Apr 26 |
|
| Compartmentalization of reactants in different regions of sodium 1,4-bis(2-ethylhexyl)sulfosuccinate/heptane/water reverse micelles and its influence on bimolecular electron-transfer kinetics. | 2007 Aug 2 |
|
| A novel composite: layered double hydroxides encapsulated in vesicles. | 2007 Dec 20 |
|
| Ultrafast energy transfer in water-AOT reverse micelles. | 2007 Dec 27 |
|
| Dye-sensitized solar cells based on nanocrystalline titania electrodes made at various sintering temperatures. | 2007 Feb |
|
| Thiol-frozen shape evolution of triangular silver nanoplates. | 2007 Feb 13 |
|
| The dispersion-stability diagram of boehmite nanoparticles in aqueous AOT solutions. | 2007 Feb 15 |
|
| Atomic force microscopy images of lyotropic lamellar phases. | 2007 Feb 7 |
|
| Comparative study of the photophysical behavior of fisetin in homogeneous media and in anionic and cationic reverse micelles media. | 2007 May-Jun |
|
| Improvement in extraction and catalytic activity of Mucor javanicus lipase by modification of AOT reverse micelle. | 2007 Nov |
|
| Site-specific hydration status of an amphipathic peptide in AOT reverse micelles. | 2007 Oct 23 |
|
| Ultrasound induced formation of paraffin emulsion droplets as template for the preparation of porous zirconia. | 2007 Sep |
|
| The effect of changing the microstructure of a microemulsion on chemical reactivity. | 2007 Sep 11 |
|
| On the possibility that cyclodextrins' chiral cavities can be available on AOT n-heptane reverse micelles. A UV-visible and induced circular dichroism study. | 2007 Sep 13 |
|
| Synthesis and characterization of one-dimensional CdSe by a novel reverse micelle assisted hydrothermal method. | 2008 Apr 15 |
|
| P450cam biocatalysis in surfactant-stabilized two-phase emulsions. | 2008 Apr 15 |
|
| The spectrophotometric study of the binding of vitamin E to water + dimethyl sulfoxide and water + diethyl sulfoxide containing reversed micelles. | 2008 Apr 2 |
|
| Molecular dynamics simulations of AOT-water/formamide reverse micelles: structural and dynamical properties. | 2008 Dec 28 |
|
| Micellization and synergistic interaction of binary surfactant mixtures based on sodium nonylphenol polyoxyethylene ether sulfate. | 2008 Feb 15 |
|
| Kinetics of the photosensitized oxidation of chymotrypsin in different media. | 2008 Jan |
|
| On the investigation of the bilayer functionalities of 1,2-di-oleoyl-sn-glycero-3-phosphatidylcholine (DOPC) large unilamellar vesicles using cationic hemicyanines as optical probes: a wavelength-selective fluorescence approach. | 2008 Jan 1 |
|
| Fourier transform infrared spectroscopy of azide and cyanate ion pairs in AOT reverse micelles. | 2008 Jul 14 |
|
| Design and control of patterns in reaction-diffusion systems. | 2008 Jun |
|
| Optical sensor of anionic surfactants using solid-phase extraction with a lactone-form rhodamine B membrane. | 2008 Jun |
|
| Fluorescence anisotropy of ionic probes in AOT reverse micelles: influence of water droplet size and electrostatic interactions on probe dynamics. | 2008 Jun 19 |
|
| Modulation of dynamics and reactivity of water in reverse micelles of mixed surfactants. | 2008 Oct 16 |
|
| Fine control over the morphology and structure of mesoporous silica nanomaterials by a dual-templating approach. | 2008 Oct 7 |
|
| Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. I. Effect of the hemicyanines' structure. | 2009 Apr 2 |
|
| Physico-chemical investigation of nanostructures in liquid phases: nickel chloride ionic clusters confined in sodium bis(2-ethylhexyl) sulfosuccinate reverse micelles. | 2009 Aug 1 |
|
| Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. II: Effect of the surfactant. | 2009 May 14 |
|
| Modulation of excited-state proton-transfer reactions of 7-hydroxy-4-methylcoumarin in ionic and nonionic reverse micelles. | 2009 May 14 |
|
| Complexes between high charge density cationic polyelectrolytes and anionic single- and double-tail surfactants. | 2009 May 21 |
|
| Study of the factors affecting the extraction of soybean protein by reverse micelles. | 2010 Feb |
Patents
Sample Use Guides
Usual Adult Dose for Constipation:
Oral: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 200 to 283 mg rectally administered as an enema once or twice. Alternative: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day.
Usual Pediatric Dose for Constipation:
Oral: less than 3 years: 10 to 40 mg (docusate sodium) orally divided in 1 to 4 doses. 3 to 6 years: 20 to 60 mg (docusate sodium) orally divided in 1 to 4 doses. 6 to 12 years: 40 to 150 mg (docusate sodium) orally divided in 1 to 4 doses. greater than 12 years: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 3 to 18 years: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day. Alternative: 200 to 283 mg rectally administered as an enema once daily as needed for constipation.
Route of Administration:
Other
It was evaluated the efficacy and toxicity of docusate against herpes simplex viruses (HSV). Docusate was effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2 with EC(90-100) (effective concentration giving 90-100% virus yield reduction) of approximately 0.005% (w/v). The cytotoxicity profiles of docusate were time- and dose-dependent and thus associated with the frequency of use. Kinetics of inactivation examined by pre-mixing virus and drug in a time-course experiment demonstrated that docusate could reach its EC(90-100) within 30 min.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29699
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01806MIG
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL1477036
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
31407
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
m4715
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
1224700
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
6K7YS503HC
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
C28999
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
128-49-4
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
100000087522
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
204-889-8
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
82001
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT001505
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
DTXSID2044212
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY | |||
|
6K7YS503HC
Created by
admin on Sat Dec 16 05:07:40 GMT 2023 , Edited by admin on Sat Dec 16 05:07:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
